Bank of Montreal Can Boosts Edwards Lifesciences Stake

Institutional investor increases position in medical research company by 23.3%

Mar. 13, 2026 at 7:27am

Got story updates? Submit your updates here. ›

Bank of Montreal Can, an institutional investor, has increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 23.3% during the third quarter, according to a recent 13F filing with the SEC. The investor now owns 844,155 shares of the medical research company's stock, valued at approximately $65.65 million.

Why it matters

Edwards Lifesciences is a leading medical technology company focused on structural heart disease and critical care monitoring. The increase in ownership by a major institutional investor like Bank of Montreal Can signals confidence in the company's growth prospects and long-term potential.

The details

According to the 13F filing, Bank of Montreal Can added 159,257 shares to its existing position in Edwards Lifesciences during the third quarter. The investor now owns approximately 0.15% of the company's outstanding shares. Edwards Lifesciences is known for its innovative prosthetic heart valves and transcatheter aortic valve replacement (TAVR) technologies, which have been driving the company's growth in recent years.

  • The 13F filing was submitted in the third quarter of the year.

The players

Bank of Montreal Can

A major Canadian financial institution and institutional investor.

Edwards Lifesciences Corporation

A leading medical technology company focused on structural heart disease and critical care monitoring.

Got photos? Submit your photos here. ›

The takeaway

The increase in ownership by Bank of Montreal Can in Edwards Lifesciences reflects the institutional investor's confidence in the medical technology company's long-term growth potential. As a leader in innovative heart valve and TAVR technologies, Edwards Lifesciences continues to attract interest from major investors.